Macrophage senescence in diabetic kidney disease: an identity gap and a testable, phase-dependent framework

Cellular senescence is increasingly invoked to explain premature aging of the diabetic kidney. Kidney macrophages accumulate early in diabetic kidney disease (DKD), drive tubulointerstitial inflammation, and share senescence-inducing stressors with parenchymal cells. Although senescence-associated features have been reported in DKD macrophages, senescent macrophages meeting consensus multi-marker criteria remain unconfirmed in human DKD. This identity gap motivates our review: multi-marker, spatially resolved evidence anchored to lineage identity is needed before macrophage senescence can be accepted as a therapeutic target. We propose that, if macrophage senescence occurs, its functional meaning depends on disease phase. Early senescence programs may be adaptive and reversible. During progression, tubule–macrophage vesicle exchange, early fibrosis-associated macrophage phenotypic switching (including macrophage-to-myofibroblast transition), and divergence between trained immunity and terminal arrest may determine resolution or propagation. In established DKD, senescence-associated secretory phenotype (SASP)–NLRP3 feedback, ferroptosis coupling, and failed immunosurveillance may sustain pathology. This framework implies phase-matched strategies: senomorphics early, biomarker-timed blockade of extracellular-vesicle senescence propagation during progression, and intermittent macrophage-directed senolysis in established disease. It yields three falsifiable predictions: senolytic benefit will invert with phase; biomarker enrichment will amplify treatment responses; and the p21 high macrophage subset will be protective early but not late. We grade each mechanistic link by how directly it implicates macrophages and distinguish human DKD evidence from preclinical inference throughout. Testing these predictions will determine whether the framework holds.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.2020955
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Macrophage senescence in diabetic kidney disease: an identity gap and a testable, phase-dependent framework

Xiaomeng Lin, Changlin Li, 李文婷, Qiang He
3 links
Frontiers in Immunology
Chronic Kidney Disease and Diabetes
article

Macrophage senescence in diabetic kidney disease: an identity gap and a testable, phase-dependent framework

Xiaomeng Lin, Changlin Li, 李文婷, Qiang He
article en

Abstract

Cellular senescence is increasingly invoked to explain premature aging of the diabetic kidney. Kidney macrophages accumulate early in diabetic kidney disease (DKD), drive tubulointerstitial inflammation, and share senescence-inducing stressors with parenchymal cells. Although senescence-associated features have been reported in DKD macrophages, senescent macrophages meeting consensus multi-marker criteria remain unconfirmed in human DKD. This identity gap motivates our review: multi-marker, spatially resolved evidence anchored to lineage identity is needed before macrophage senescence can be accepted as a therapeutic target. We propose that, if macrophage senescence occurs, its functional meaning depends on disease phase. Early senescence programs may be adaptive and reversible. During progression, tubule–macrophage vesicle exchange, early fibrosis-associated macrophage phenotypic switching (including macrophage-to-myofibroblast transition), and divergence between trained immunity and terminal arrest may determine resolution or propagation. In established DKD, senescence-associated secretory phenotype (SASP)–NLRP3 feedback, ferroptosis coupling, and failed immunosurveillance may sustain pathology. This framework implies phase-matched strategies: senomorphics early, biomarker-timed blockade of extracellular-vesicle senescence propagation during progression, and intermittent macrophage-directed senolysis in established disease. It yields three falsifiable predictions: senolytic benefit will invert with phase; biomarker enrichment will amplify treatment responses; and the p21 high macrophage subset will be protective early but not late. We grade each mechanistic link by how directly it implicates macrophages and distinguish human DKD evidence from preclinical inference throughout. Testing these predictions will determine whether the framework holds.

Frontiers in ImmunologyVol. 17
Zhejiang Chinese Medical University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province
Good health and well-being
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon